Page last updated: 2024-10-31

nafamostat and Acute Disease

nafamostat has been researched along with Acute Disease in 54 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Acute Disease: Disease having a short and relatively severe course.

Research Excerpts

ExcerptRelevanceReference
"Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups."9.15Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? ( Cho, M; Choi, CW; Chung, CW; Kang, DH; Kim, DU; Kim, HW; Park, KT; Park, SB; Yoon, KT, 2011)
"Long-term effects of nafamostat mesylate, a protease inhibitor, and imipenem, an antibiotic, on trypsintaurocholate-induced acute pancreatitis were studied in rats."7.70Long-term effects of nafamostat and imipenem on experimental acute pancreatitis in rats. ( Hayakawa, T; Ishiguro, H; Kitagawa, M; Naruse, S; Ozaki, T; Seki, Y; Wang, Y, 2000)
"This study was undertaken to determine whether synthetic proteinase inhibitors--nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) have any influence on multiorgan oxidant-antioxidant balance in acute haemorrhagic pancreatitis induced in Wistar rats using a retrograde intraductal injection of 5% Na-taurocholate."7.69The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. ( Dabrowski, A; Gabryelewicz, A, 1994)
" infusion performed 1 h after intrabiliary injection of enterokinase/sodium taurocholate to induce acute pancreatitis (AP): (1) Saline; (2) 5 micrograms/kg/h nafamostat mesilate (FUT-175); (3) 10 micrograms/kg/h FUT-175; and (4) 25 micrograms/kg/h FUT-175."7.69Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress. ( Chui, DH; Fesce, E; Idéo, G; Marotta, F; Rezakovic, I; Suzuki, K, 1994)
"Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis."7.69Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995)
"The aim of this study was to investigate the effect of Nafamostat mesilate (FUT-175) on some blood platelet properties during the first hours of acute experimental pancreatitis (AEP) in dogs."7.68Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175). ( Bielawiec, M; Bodzenta-Lukaszyk, A; Gabryelewicz, A; Lukaszyk, A, 1992)
"FUT has been reported as a drug for the treatments of DIC (disseminated intravascular coagulation) and acute pancreatitis and as an anticoagulant in extracorporeal circulation."6.41[Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation]. ( Tsukagoshi, S, 2000)
"Mizoribine has been recognized to have an acceptable toxicity profile compared with other immunosuppressants."5.35A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. ( Ebihara, K; Mori, S, 2008)
"Acute pancreatitis was induced in 13 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct."5.28Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis. ( Babicki, A; Basinski, A; Dobosz, M; Juszkiewicz, P; Sledzinski, Z; Stanek, A; Wajda, Z, 1991)
" Nafamostat mesylate (nafamostat) is a drug licensed in Japan and Korea for indications including acute pancreatitis and disseminated intravascular coagulation."5.22Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review. ( Bowen, AC; Denholm, JT; Dore, GJ; Hernández-Mitre, MP; Hills, TE; Lewin, SR; McQuilten, Z; Morpeth, SC; Paterson, DL; Roberts, JA; Tong, SYC; Venkatesh, B, 2022)
"Infusion of the protease inhibitor nafamostat mesilate (20 mg) effectively prevents post-ERCP pancreatitis, but only in low-risk groups."5.15Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? ( Cho, M; Choi, CW; Chung, CW; Kang, DH; Kim, DU; Kim, HW; Park, KT; Park, SB; Yoon, KT, 2011)
"This study was conducted to determine whether continuous regional arterial infusion (CRAI) of the protease inhibitor, nafamostat mesylate, in acute necrotizing pancreatitis, would reduce mortality."5.08Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. ( Kakugawa, Y; Matsuno, S; Sunamura, M; Takeda, K, 1996)
"The proteolytic enzyme inhibitor nafamostat mesylate is widely used for the treatment of acute pancreatitis and disseminated intravascular coagulation."4.31Identification of Risk Factors for Phlebitis in Patients Treated with Nafamostat Mesylate. ( Kawakami, Y; Kotake, K; Tahira, A, 2023)
"Nafamostat mesilate (NM), a synthetic broad-spectrum serine protease inhibitor, has been commonly used for treating acute pancreatitis (AP) and other inflammatory-associated diseases in some East Asia countries."4.31Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation. ( Chen, P; He, WQ; Huang, L; Liu, Y; Ren, JD; Tang, YR; Zhao, LJ, 2023)
"The established referred allodynia/hyperalgesia following cerulein treatment was abolished by post-treatment with nafamostat mesilate, a proteinase inhibitor, and with capsazepine, a TRPV1 antagonist, in mice."3.76The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice. ( Akashi, R; Ishikura, H; Kawabata, A; Kitamura, T; Matsumura, K; Matsunami, M; Naruse, M; Nishimura, S; Sekiguchi, F; Shinozaki, Y, 2010)
"We treated five patients with severe acute pancreatitis by continuous arterial infusion (CAI) of protease inhibitor, nafamostat mesilate."3.70[Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin]. ( Fukui, K; Hara, A; Ichikawa, M; Ito, T; Matsukawa, H; Okuda, S; Sato, K; Seki, H; Shiraga, N; Takizawa, K; Yamataka, K; Yoshioka, M, 1998)
"Long-term effects of nafamostat mesylate, a protease inhibitor, and imipenem, an antibiotic, on trypsintaurocholate-induced acute pancreatitis were studied in rats."3.70Long-term effects of nafamostat and imipenem on experimental acute pancreatitis in rats. ( Hayakawa, T; Ishiguro, H; Kitagawa, M; Naruse, S; Ozaki, T; Seki, Y; Wang, Y, 2000)
"This study was undertaken to determine whether synthetic proteinase inhibitors--nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) have any influence on multiorgan oxidant-antioxidant balance in acute haemorrhagic pancreatitis induced in Wistar rats using a retrograde intraductal injection of 5% Na-taurocholate."3.69The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. ( Dabrowski, A; Gabryelewicz, A, 1994)
"Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis."3.69Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995)
" infusion performed 1 h after intrabiliary injection of enterokinase/sodium taurocholate to induce acute pancreatitis (AP): (1) Saline; (2) 5 micrograms/kg/h nafamostat mesilate (FUT-175); (3) 10 micrograms/kg/h FUT-175; and (4) 25 micrograms/kg/h FUT-175."3.69Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress. ( Chui, DH; Fesce, E; Idéo, G; Marotta, F; Rezakovic, I; Suzuki, K, 1994)
"The effect of FUT-175, a new synthetic trypsin inhibitor, was evaluated in a lethal model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented diet (CDE diet)."3.68Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice. ( Frey, CF; Isaji, S; Ruebner, B; Stanten, R; Suzuki, M, 1992)
"The aim of this study was to investigate the effect of Nafamostat mesilate (FUT-175) on some blood platelet properties during the first hours of acute experimental pancreatitis (AEP) in dogs."3.68Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175). ( Bielawiec, M; Bodzenta-Lukaszyk, A; Gabryelewicz, A; Lukaszyk, A, 1992)
"To confirm that trypsin activity is a most important initiating factor in closed duodenal loop pancreatitis in rats, we observed the course of acute pancreatitis when trypsinogen activation was inhibited by intraduodenal infusion of a potent synthetic trypsin inhibitor (TI, nafamostat mesilate) but the other conditions were left unchanged."3.68Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat. ( Hayakawa, T; Kiriyama, S; Kitagawa, M; Kondo, T; Ono, H; Sakai, Y; Shibata, T; Sobajima, H, 1990)
"FUT has been reported as a drug for the treatments of DIC (disseminated intravascular coagulation) and acute pancreatitis and as an anticoagulant in extracorporeal circulation."2.41[Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation]. ( Tsukagoshi, S, 2000)
" We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute cardiac or respiratory failure."1.37Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. ( Han, SJ; Hong, KS; Kim, HS; Kim, KI; Lee, SH; Lee, WK; Whang, SM, 2011)
"Mizoribine has been recognized to have an acceptable toxicity profile compared with other immunosuppressants."1.35A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. ( Ebihara, K; Mori, S, 2008)
"The Japanese severity score (JSS) for acute pancreatitis was revised in 2008."1.35Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis. ( Kamei, K; Ku, Y; Kuroda, Y; Ohyanagi, H; Satoi, S; Sawa, H; Shinzeki, M; Takeyama, Y; Ueda, T; Yasuda, T, 2009)
"However, she died of multiple organ failure and systemic cytomegalovirus infection in the chronic stage."1.32[Fulminant myocarditis treated with percutaneous cardiopulmonary support and long-term complications: three case reports]. ( Kusaba, T; Matsumuro, A; Nakahara, Y; Nakamura, T; Sawada, S, 2004)
"The major cause of death in acute pancreatitis is severe infection owing to bacterial translocation."1.31Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model. ( Isaji, S; Takagi, K, 2000)
"Acute pancreatitis was induced in 19 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct."1.28Synthetic antiproteases in acute pancreatitis: an experimental study. ( Babicki, A; Basiński, A; Dobosz, M; Juszkiewicz, P; Sledziński, Z; Wajda, Z, 1992)
"Acute pancreatitis was induced in 13 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct."1.28Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis. ( Babicki, A; Basinski, A; Dobosz, M; Juszkiewicz, P; Sledzinski, Z; Stanek, A; Wajda, Z, 1991)
"The coagulo-fibrinolytic changes after acute pancreatitis was induced by the intraductal injection of an autologous bile and trypsin mixture showed decreased platelet counts, decreased plasma fibrinogen levels, prolonged partial prothrombin time and increased fibrinogen degradation products."1.28Effect of a synthetic protease inhibitor (Fut-175) on coagulation abnormalities during experimental acute pancreatitis in dogs. ( Ha, S; Haku, A; Hiura, A; Nishiwaki, H; Satake, K; Umeyama, K, 1990)
" When a new synthetic antiprotease (nafamstat mesilate) in a dosage of 0."1.27Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect. ( Koh, I; Nishiwaki, H; Satake, K; Umeyama, K, 1985)

Research

Studies (54)

TimeframeStudies, this research(%)All Research%
pre-19907 (12.96)18.7374
1990's24 (44.44)18.2507
2000's15 (27.78)29.6817
2010's5 (9.26)24.3611
2020's3 (5.56)2.80

Authors

AuthorsStudies
Hernández-Mitre, MP1
Tong, SYC1
Denholm, JT1
Dore, GJ1
Bowen, AC1
Lewin, SR1
Venkatesh, B1
Hills, TE1
McQuilten, Z1
Paterson, DL1
Morpeth, SC1
Roberts, JA1
Kotake, K1
Tahira, A1
Kawakami, Y1
Chen, P1
Zhao, LJ1
Huang, L1
He, WQ1
Tang, YR1
Liu, Y1
Ren, JD1
Mori, S1
Ebihara, K1
Ueda, T1
Takeyama, Y1
Yasuda, T1
Kamei, K1
Satoi, S1
Sawa, H1
Shinzeki, M1
Ku, Y1
Kuroda, Y1
Ohyanagi, H1
Piaścik, M1
Rydzewska, G2
Milewski, J1
Olszewski, S1
Furmanek, M1
Walecki, J1
Gabryelewicz, A4
Nishimura, S1
Ishikura, H1
Matsunami, M1
Shinozaki, Y1
Sekiguchi, F1
Naruse, M1
Kitamura, T1
Akashi, R1
Matsumura, K1
Kawabata, A1
Han, SJ1
Kim, HS1
Kim, KI1
Whang, SM1
Hong, KS1
Lee, WK1
Lee, SH1
Park, KT1
Kang, DH1
Choi, CW1
Cho, M1
Park, SB1
Kim, HW1
Kim, DU1
Chung, CW1
Yoon, KT1
Hamada, Y1
Imaizumi, H2
Miyazawa, S1
Kida, M2
Souma, K1
Koizumi, W1
Sunakawa, K1
Kuroyama, M1
Kotani, K1
Ichiba, S1
Andou, M1
Sano, Y1
Date, H1
Tedoriya, T1
Goto, K1
Shimizu, N1
Imamura, T1
Yoshida, H1
Ishikawa, A1
Katayose, K1
Nozu, F1
Kitamura, K1
Ikegami, A1
Takahashi, A1
Niikawa, J1
Tanaka, S1
Ishii, H1
Hoshino, M1
Kusano, M1
Matsui, S1
Hashimoto, T1
Mitamura, K1
Nishimaki, H1
Okuno, J1
Kataoka, Y1
Kida, Y1
Soma, K1
Saigenji, K1
Kusaba, T1
Nakahara, Y1
Matsumuro, A1
Nakamura, T1
Sawada, S1
Inoue, K1
Yoshiba, M1
Kohsaki, T1
Nishimori, I1
Onishi, S1
Takeda, K5
Nakae, H1
Tajimi, K1
Iwaki, M2
Ozeki, M2
Sato, T2
Suzuki, K2
Motoyoshi, A2
Suzuki, S1
Fujita, M1
Aoyama, T2
Araida, T1
Frey, CF2
Ruebner, B2
Carlson, J1
King, J1
Marotta, F1
Fesce, E1
Rezakovic, I1
Chui, DH1
Idéo, G1
Nakae, Y1
Naruse, S2
Kitagawa, M3
Hirao, S1
Yamamoto, R1
Hayakawa, T3
Dabrowski, A1
Kitagawa, H1
Chang, H1
Fujita, T1
Morishima, I1
Sassa, H1
Sone, T1
Tsuboi, H1
Kondo, J1
Koyama, T1
Ogawa, M1
Mori, Y1
Ueda, S1
Mori, T1
Makino, Y1
Hori, J1
Ohto, M1
Wakashin, M1
Matsuno, S4
Sunamura, M2
Kakugawa, Y4
Kawasaki, K1
Arimura, Y1
Hirata, H1
Suzuki, T1
Kakumoto, Y1
Kaneto, H1
Mihara, M1
Imai, K1
Matsukawa, H1
Hara, A1
Ito, T1
Fukui, K1
Sato, K1
Ichikawa, M1
Yoshioka, M1
Seki, H1
Yamataka, K1
Takizawa, K1
Okuda, S1
Shiraga, N1
Hongo, H1
Takano, H1
Imai, A1
Yamaguchi, T1
Boku, Y1
Fujii, T1
Naito, Y1
Yoshida, N1
Yoshikawa, T1
Kondo, M1
Zhang, JP1
Blum, MG1
Chang, AC1
Shyr, Y1
Blair, KS1
Awwad, M1
Pierson, RN1
Tsukagoshi, S1
Kistler, EB1
Lefer, AM1
Hugli, TE1
Schmid-Schönbein, GW1
Takagi, K1
Isaji, S2
Wang, Y1
Ishiguro, H1
Seki, Y1
Ozaki, T1
Nakase, H1
Itani, T1
Mimura, J1
Kawasaki, T1
Komori, H1
Okazaki, K1
Chiba, T1
Hirano, T1
Manabe, T1
Tobe, T1
Kashima, K1
Kataoka, K1
Umehara, K1
Suzuki, M1
Stanten, R1
Lukaszyk, A1
Bodzenta-Lukaszyk, A1
Bielawiec, M1
Yanamoto, H1
Kikuchi, H1
Sato, M1
Shimizu, Y1
Yoneda, S1
Okamoto, S1
Murakawa, M1
Okamura, T1
Shibuya, T1
Harada, M1
Otsuka, T1
Niho, Y1
Yoshida, K1
Toki, F1
Takeuchi, T1
Dobosz, M2
Sledziński, Z2
Babicki, A2
Juszkiewicz, P2
Basiński, A2
Wajda, Z2
Stanek, A1
Kawaguchi, S1
Kobari, M3
Satake, K2
Ha, S1
Hiura, A1
Nishiwaki, H2
Haku, A1
Umeyama, K2
Ono, H1
Kondo, T1
Shibata, T1
Sakai, Y1
Kiriyama, S1
Sobajima, H1
Ino, Y1
Kurumi, M1
Wisner, JR1
Ozawa, S1
Renner, IG1
Prokopowicz, J1
Bodzenta, A1
Bielecki, W1
Koh, I1

Reviews

5 reviews available for nafamostat and Acute Disease

ArticleYear
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
    Clinical pharmacokinetics, 2022, Volume: 61, Issue:10

    Topics: Acute Disease; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Fibrinolytic Agents; Guanidi

2022
[Blood purification for patients with chronic renal failure accompanied by severe liver disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 6

    Topics: Acute Disease; Anticoagulants; Benzamidines; Carrier State; Cellulose; Chronic Disease; Dialysis Sol

2004
[Treatment of acute pancreatitis with protease inhibitor, H2 receptor antagonist and somatostatin analogue].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:11

    Topics: Acute Disease; Aprotinin; Benzamidines; Cimetidine; Drug Administration Schedule; Drug Therapy, Comb

2004
[Continuous regional arterial infusion of protease inhibitor and antibiotic for severe acute pancreatitis].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:11

    Topics: Acute Disease; Angiography; Anti-Bacterial Agents; Benzamidines; Clinical Trials as Topic; Guanidine

2004
[Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:5

    Topics: Acute Disease; Adult; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Extracor

2000

Trials

4 trials available for nafamostat and Acute Disease

ArticleYear
The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study.
    Pancreas, 2010, Volume: 39, Issue:6

    Topics: Acute Disease; Anti-Bacterial Agents; Benzamidines; Drug Administration Schedule; Drug Therapy, Comb

2010
Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
    Pancreas, 2011, Volume: 40, Issue:8

    Topics: Acute Disease; Aged; Amylases; Benzamidines; Cholangiopancreatography, Endoscopic Retrograde; Dose-R

2011
Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis.
    American journal of surgery, 1996, Volume: 171, Issue:4

    Topics: Acute Disease; Adult; Anti-Bacterial Agents; Benzamidines; Drainage; Female; Guanidines; Humans; Imi

1996
Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage.
    Neurosurgery, 1992, Volume: 30, Issue:3

    Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Cerebral Angiogra

1992

Other Studies

45 other studies available for nafamostat and Acute Disease

ArticleYear
Identification of Risk Factors for Phlebitis in Patients Treated with Nafamostat Mesylate.
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2023, May-01, Volume: 143, Issue:5

    Topics: Acute Disease; Guanidines; Humans; Pancreatitis; Risk Factors

2023
Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2023, Volume: 72, Issue:9

    Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Ceruletide; Histone Deacetylase 6; Inflammasomes;

2023
A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis.
    Modern rheumatology, 2008, Volume: 18, Issue:6

    Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Benzamidines; Diabetic Ketoacidosis; Drug Therapy, Combi

2008
Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis.
    Journal of gastroenterology, 2009, Volume: 44, Issue:5

    Topics: Acute Disease; Benzamidines; Enteral Nutrition; Female; Guanidines; Humans; Infusions, Intra-Arteria

2009
The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice.
    Life sciences, 2010, Nov-20, Volume: 87, Issue:19-22

    Topics: Acute Disease; Animals; Benzamidines; Capsaicin; Ceruletide; Disease Models, Animal; Gene Expression

2010
Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.
    Journal of Korean medical science, 2011, Volume: 26, Issue:7

    Topics: Acute Disease; Anticoagulants; Benzamidines; Dose-Response Relationship, Drug; Extracorporeal Membra

2011
Compatibility of carbapenem antibiotics with nafamostat mesilate in arterial infusion therapy for severe acute pancreatitis: stabilities of carbapenem antibiotics.
    The Japanese journal of antibiotics, 2012, Volume: 65, Issue:4

    Topics: Acute Disease; Benzamidines; Carbapenems; Drug Stability; Guanidines; Humans; Infusions, Intra-Arter

2012
Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation.
    The Journal of thoracic and cardiovascular surgery, 2002, Volume: 124, Issue:3

    Topics: Acute Disease; Adult; Anticoagulants; Benzamidines; Combined Modality Therapy; Extracorporeal Membra

2002
[A case with severe acute pancreatitis treated by regional arterial infusion of nafamostat mesilate and imipenem via both celiac artery and superior mesenteric artery].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2002, Volume: 99, Issue:9

    Topics: Acute Disease; Aged; Benzamidines; Celiac Artery; Cilastatin; Cilastatin, Imipenem Drug Combination;

2002
Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit.
    Pancreas, 2004, Volume: 28, Issue:4

    Topics: Acute Disease; Anti-Bacterial Agents; Benzamidines; Drug Therapy, Combination; Female; Guanidines; H

2004
[Fulminant myocarditis treated with percutaneous cardiopulmonary support and long-term complications: three case reports].
    Journal of cardiology, 2004, Volume: 43, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Benzamidines; Cardiopulmonary Bypass; Fatal

2004
Correlation between serum nafamostat mesilate and activated coagulation time during continuous hemodiafiltration.
    Artificial organs, 2005, Volume: 29, Issue:4

    Topics: Acute Disease; Anticoagulants; Benzamidines; Diatomaceous Earth; Female; Guanidines; Hemodiafiltrati

2005
[Pharmacological studies of FUT-175, nafamstat mesilate. II. Effects on experimental acute pancreatitis].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1984, Volume: 84, Issue:4

    Topics: Acute Disease; Amylases; Animals; Benzamidines; Blood Glucose; Blood Pressure; Dogs; Female; Guanidi

1984
Therapeutic regimens in acute experimental pancreatitis in rats: effects of a protease inhibitor, a beta-agonist, and antibiotics.
    Pancreas, 1995, Volume: 11, Issue:2

    Topics: Acute Disease; Adrenergic beta-Agonists; Amylases; Animals; Benzamidines; Diatrizoate Meglumine; Ent

1995
Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress.
    International journal of pancreatology : official journal of the International Association of Pancreatology, 1994, Volume: 16, Issue:1

    Topics: Acute Disease; Animals; Benzamidines; Dextrans; Fluorescein-5-isothiocyanate; Guanidines; Male; Panc

1994
Activation of trypsinogen in experimental models of acute pancreatitis in rats.
    Pancreas, 1995, Volume: 10, Issue:3

    Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Ceruletide; Disease Models, Animal; Guan

1995
The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 1994, Volume: 45, Issue:3

    Topics: Acute Disease; Animals; Benzamidines; Gabexate; Guanidines; Lung; Male; Malondialdehyde; Oxidative S

1994
Hyperkalemia due to nafamostat mesylate.
    The New England journal of medicine, 1995, Mar-09, Volume: 332, Issue:10

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Guanidines; Humans; Hype

1995
A case of fulminant myocarditis rescued--by long-term percutaneous cardiopulmonary support.
    Japanese circulation journal, 1994, Volume: 58, Issue:6

    Topics: Acute Disease; Adult; Antithrombins; Benzamidines; Complement Inactivator Proteins; Guanidines; Hear

1994
Protective effects of FUT-175 on acute massive hepatic necrosis induced in mice following endotoxin injection and immunization with liver proteins.
    Journal of hepatology, 1993, Volume: 19, Issue:3

    Topics: Acute Disease; Animals; Autoimmune Diseases; Benzamidines; Chemical and Drug Induced Liver Injury; E

1993
[Marked improvement of "severe acute pancreatitis" with continuous administration of protease inhibitor: nafamostat mesilate (Futhan) via intraarterial infusion in a case].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1996, Volume: 93, Issue:8

    Topics: Acute Disease; Benzamidines; Guanidines; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancr

1996
[Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1998, Volume: 95, Issue:11

    Topics: Acute Disease; Adult; Benzamidines; Drug Therapy, Combination; Glycoproteins; Guanidines; Humans; In

1998
Pancreatic phospholipase A2 induces bacterial translocation in rats.
    Immunopharmacology and immunotoxicology, 1999, Volume: 21, Issue:4

    Topics: Acute Disease; Animals; Bacterial Translocation; Benzamidines; Cecum; Guanidines; Injections, Intrap

1999
Immunohistologic evaluation of mechanisms mediating hyperacute lung rejection, and the effect of treatment with K76-COOH, FUT-175, and anti-Gal column immunoadsorption.
    Xenotransplantation, 1999, Volume: 6, Issue:4

    Topics: Acute Disease; Animals; Benzamidines; Blood Transfusion; Complement Inactivator Proteins; Galactosid

1999
Plasma activation during splanchnic arterial occlusion shock.
    Shock (Augusta, Ga.), 2000, Volume: 14, Issue:1

    Topics: Acute Disease; Animals; Arterial Occlusive Diseases; Benzamidines; Biological Factors; Cats; Celiac

2000
Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model.
    Pancreas, 2000, Volume: 21, Issue:3

    Topics: Acute Disease; Amylases; Animals; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocati

2000
Long-term effects of nafamostat and imipenem on experimental acute pancreatitis in rats.
    Pancreas, 2000, Volume: 21, Issue:3

    Topics: Acute Disease; Animals; Bacterial Infections; Benzamidines; Colony Count, Microbial; Escherichia col

2000
Successful treatment of severe acute pancreatitis by the combination therapy of continuous arterial infusion of a protease inhibitor and continuous hemofiltration.
    Journal of gastroenterology and hepatology, 2001, Volume: 16, Issue:8

    Topics: Acute Disease; Aged; Benzamidines; Combined Modality Therapy; Guanidines; Hemofiltration; Humans; In

2001
[The cellular and lysosomal fragility of pancreatic acinar cells after ligation of pancreatico-biliary duct in the rat and the protective effects of nafamostat mesilate].
    Nihon Geka Gakkai zasshi, 1992, Volume: 93, Issue:12

    Topics: Acute Disease; Amylases; Animals; Benzamidines; Body Water; Cathepsin B; Disease Models, Animal; Gua

1992
[Treatment of acute pancreatitis].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1992, Dec-10, Volume: 81, Issue:12

    Topics: Acute Disease; Benzamidines; Disseminated Intravascular Coagulation; Drainage; Gabexate; Glycoprotei

1992
Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice.
    International journal of pancreatology : official journal of the International Association of Pancreatology, 1992, Volume: 11, Issue:1

    Topics: Acute Disease; Amylases; Animals; Benzamidines; Choline; Choline Deficiency; Diet; Ethionine; Female

1992
Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175).
    Thrombosis research, 1992, Jan-15, Volume: 65, Issue:2

    Topics: Acute Disease; Animals; Benzamidines; Blood Platelets; Dogs; Guanidines; Male; Pancreatitis; Platele

1992
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
    Annals of hematology, 1992, Volume: 64, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benz

1992
[Antienzyme preparations in the treatment of acute pancreatitis].
    Nihon rinsho. Japanese journal of clinical medicine, 1990, Volume: 48, Issue:1

    Topics: Acute Disease; Adult; Aprotinin; Benzamidines; Cytidine Diphosphate Choline; Disseminated Intravascu

1990
Synthetic antiproteases in acute pancreatitis: an experimental study.
    The Mount Sinai journal of medicine, New York, 1992, Volume: 59, Issue:1

    Topics: Acute Disease; Animals; Benzamidines; Dogs; Gabexate; Guanidines; Hemodynamics; Hemorrhage; Pancreat

1992
Beneficial effect of therapeutic infusion of nafamostat mesilate (FUT-175) on hemodynamics in experimental acute pancreatitis.
    Hepato-gastroenterology, 1991, Volume: 38, Issue:2

    Topics: Acute Disease; Animals; Benzamidines; Dogs; Guanidines; Hemodynamics; Infusions, Intravenous; Male;

1991
[Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis induced by closed duodenal loop obstruction].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1990, Volume: 87, Issue:6

    Topics: Acute Disease; Animals; Benzamidines; Dogs; Guanidines; Infusions, Intra-Arterial; Necrosis; Pancrea

1990
Effect of a synthetic protease inhibitor (Fut-175) on coagulation abnormalities during experimental acute pancreatitis in dogs.
    Gastroenterologia Japonica, 1990, Volume: 25, Issue:6

    Topics: Acute Disease; Animals; Benzamidines; Blood Coagulation Disorders; Blood Coagulation Factors; Blood

1990
Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat.
    Digestive diseases and sciences, 1990, Volume: 35, Issue:6

    Topics: Acute Disease; Animals; Benzamidines; Duodenum; Guanidines; Injections; Male; Pancreas; Pancreatitis

1990
Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats.
    Japanese journal of pharmacology, 1986, Volume: 41, Issue:2

    Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Guanidines; Male; Pancreas; Pancreatitis

1986
The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat.
    International journal of pancreatology : official journal of the International Association of Pancreatology, 1989, Volume: 4, Issue:4

    Topics: Acute Disease; Animals; Benzamidines; Ceruletide; Chymotrypsinogen; Guanidines; Male; Organ Size; Pa

1989
Continuous arterial infusion of protease inhibitor for severe acute pancreatitis.
    Gastroenterologia Japonica, 1989, Volume: 24, Issue:3

    Topics: Acute Disease; Adult; Benzamidines; Female; Guanidines; Humans; Infusions, Intra-Arterial; Male; Mid

1989
Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis.
    Gastroenterologia Japonica, 1989, Volume: 24, Issue:4

    Topics: Acute Disease; Animals; Benzamidines; Dogs; Guanidines; Infusions, Intra-Arterial; Pancreatitis; Pro

1989
Effect of FUT-175 (nafamstat mesilate) on platelets in canine acute experimental pancreatitis.
    Digestion, 1988, Volume: 40, Issue:1

    Topics: Acute Disease; Animals; Benzamidines; Blood Platelets; Dogs; Guanidines; Pancreatitis; Platelet Aggr

1988
Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect.
    Digestion, 1985, Volume: 32, Issue:2

    Topics: Acute Disease; Animals; Ascitic Fluid; Benzamidines; Disease Models, Animal; Dogs; Female; Guanidine

1985